山东方坦思宣布与杨森制药达成许可协议,将开发抗IL-17A单克隆抗体并使其商业化

原文始发于微信公众号(药时代):山东方坦思宣布与杨森制药达成许可协议,将开发抗IL-17A单克隆抗体并使其商业化

山东方坦思宣布与杨森制药达成许可协议,将开发抗IL-17A单克隆抗体并使其商业化

• 杨森将其抗IL-17A单克隆抗体项目授权许可给山东方坦思

2019年12月17日

2019年12月17日- 山东方坦思生物制药有限公司(“方坦思”)今日宣布与强生公司旗下的一家杨森制药公司(“杨森”)签订独家许可、开发和商业化协议,在中华人民共和国(“中国”)包括香港特别行政区(“香港”)、澳门特别行政区(“澳门”)、台湾区域(“台湾”) 和韩国开发含有抗IL-17A单克隆抗体的医药产品并使其商业化。

“我们与杨森在开发这种新型单克隆抗体上的许可与合作反映了我们对介白素17A作为一种重要的治疗靶点的强烈兴趣,以及我们对其有着革新若干种疾病的治疗方式和显著改善我们患者的生活质量的潜力的信心,”山东方坦思的CEO褚延梁说。 “有了我们当地政府和投资者提供的承诺和资源,我相信我们与杨森的合作会是我们探索和发现新型药物帮助世界各地患者的一个崭新的开始。

关于山东方坦思生物制药有限公司

方坦思是一家国际创新型生物制药公司,位于中国济宁,并在济南设有生物医药研发基地,位置便利。公司专注于呼吸系统疾病,炎症和自身免疫性疾病和癌症为主的三个治疗领域。其愿景是成为一家综合性的生物制药公司,通过内部研发和许可/合作项目在全球范围内探索、开发、制造和商业化医疗产品。有关方坦思的更多信息,请访问http://www. fontaceapharma.com/。


Shandong Fontacea Announces License Agreement with Janssen to Develop and Commercialize Anti-IL17A Monoclonal Antibody

• Shandong Fontacea licenses Janssen’s anti-IL17A monoclonal antibody program

17th December, 2019

17thDecember, 2019 — Shandong Fontacea Biopharmaceutical Co. Ltd. (“Fontacea”) announced today that it has entered into an exclusive license development and commercialization agreement with Janssen Biotech Inc. to develop and commercialize pharmaceutical products containing a human IgG1λ anti-human IL-17A neutralizing monoclonal antibody in People’s Republic of China (“China”) including Hong Kong Special Administrative Region Hong Kong Special Administrative Region of China (“Hong Kong”) Macao Special Administrative Region Hong Kong Special Administrative Region of China (“Macao”) the region of Taiwan (“Taiwan”) and South Korea.

“Our license and collaboration with Janssen on the development of this novel monoclonal antibody reflects our strong interest in interleukin 17A as an important therapeutic target and our confidence that it has the potential to revolutionize the treatment of several disease and significantly improve the quality of life for our patients” said Mr. Yanliang ChuCEO and president of Fontacea. “With the commitment and resources provided by our local government and investors I believe this will be the beginning of our discovery and development of novel medicines to help patients around the world.”

About Shandong Fontacea Pharmaceutical Co. Ltd.

Fontacea is a biopharmaceutical company dedicated to research development and commercialization of innovative medicines for the global marketconveniently located in the Jining Hightech Zone China with a biopharmaceutical technology research & development center in Jinan. Since its inception it is dedicated to developing medicines for patients with respiratory diseases inflammatory & autoimmune diseases and cancers. Its vision is to become a fully integrated biopharmaceutical company that through both internal research and development and in-licensing/partnership programs discovers develops and commercializes novel medical products in worldwide. For more information about Fontacea visit http://www.fontaceapharma.com/.


山东方坦思宣布与杨森制药达成许可协议,将开发抗IL-17A单克隆抗体并使其商业化

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部